Antibody Based Anti-HIV-1 Microbicide Targeting a Host Protein

Development of microbicides to prevent HIV-1 transmission to women plays a valuable role in stemming the worldwide epidemic of the disease. In order to address some of the shortcomings of microbicides currently in advanced stages of clinical testing, scientists at JHU explored the development of antibodies to host cell adhesion molecules for use as anti-HIV-1 microbicide. They have identified an antibody targeting a host cell protein in which, in both in vitro and in vivo model systems, prevents sexual transmission of cell-associated HIV-1. Additionally, in the in vitro model system, this antibody also blocks the infection of susceptible cells by cell-free HIV-1 that has permeated the epithelial cell barrier that comprises the mucosal surface of the vagina and cervix. Description (Set) Proposed Use (Set) Acquired immune deficiency syndrome is the leading cause of death among persons aged 25 to 44. Every day there are approximately 16,000 new cases of HIV infection worldwide, 90% of which occurs in developing countries. The World Health Organization (WHO) estimates that 80% of HIV transmission occurs via unprotected intercourse. A preventative intervention such as the CD18 anti-HIV microbicide will reduce the incidence of new HIV-1 infections.

Inventor(s): Markham, Richard

Type of Offer: Licensing



« More Medical Patents

---